BioSpace News Archive

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc).

Accutar Biotechnology, Inc. today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton’s Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.

Jadeite Medicines Inc., a clinical stage biopharmaceutical company headquartered in Tokyo, Japan has received Orphan Drug Designation for odevixibat for the expected indication of PFIC from the Ministry of Health, Labour and Welfare of Japan.

Twist Bioscience Corporation today announced the appointment of Chet Gandhi as chief information officer.

Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.

BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution and Supply Agreement with its European partner for the Cathejell ® product, extending BioSyent Pharma’s exclusive Canadian rights to Cathejell ® until 2034.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR) today announced results from the Company’s Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoid symptoms.

Owlet (NYSE: OWLT, “the Company”), the pioneer of smart baby monitoring, announces clearance from the U.S. Food and Drug Administration (“FDA”) of BabySat™ , the first medical pulse-oximetry device featuring its advanced, wire-free sock design.

Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.

Blue Earth Therapeutics today announced upcoming presentations by the Company and a collaborator at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, to be held June 24 – 27, 2023 in Chicago, Ill.